PMID- 36030074
OWN - NLM
STAT- MEDLINE
DCOM- 20220830
LR  - 20220923
IS  - 1532-1924 (Electronic)
IS  - 1521-6926 (Linking)
VI  - 35
IP  - 1
DP  - 2022 Mar
TI  - Treatment modalities in cancer-associated venous thromboembolism (VTE).
PG  - 101354
LID - S1521-6926(22)00009-3 [pii]
LID - 10.1016/j.beha.2022.101354 [doi]
AB  - Anticoagulation is the cornerstone of cancer-associated VTE treatment, including 
      vitamin K antagonists (VKA), unfractionated heparin (UFH), fondaparinux, 
      low-molecular-weight heparins (LMWH) and direct oral anticoagulants (DOACs). The 
      goals of anticoagulant therapy in cancer patients with cancer-associated 
      thrombosis (CAT) are to improve symptoms, reduce risk of recurrent VTE or fatal 
      pulmonary embolism (PE), and decrease the risk of post-thrombotic syndrome (PTS) 
      and chronic thromboembolic pulmonary hypertension. Although LMWH have been the 
      standard of care for a long time for VTE treatment in cancer patients, showing 
      superiority over the classic VKA, in the recent years the landscape of 
      anticoagulant therapy has significantly changed with the inclusion of DOACs in 
      this population.
CI  - Copyright (c) 2022. Published by Elsevier Ltd.
FAU - Soto Alsar, Javier
AU  - Soto Alsar J
AD  - Medical Oncology Department, Hospital General Universitario Gregorio Maranon, 
      Universidad Complutense, Madrid, Spain.
FAU - Gutierrez Ortiz de la Tabla, Ana
AU  - Gutierrez Ortiz de la Tabla A
AD  - Medical Oncology Department, Hospital General Universitario Gregorio Maranon, 
      Universidad Complutense, Madrid, Spain.
FAU - Ortega Moran, Laura
AU  - Ortega Moran L
AD  - Medical Oncology Department, Hospital General Universitario Gregorio Maranon, 
      Universidad Complutense, Madrid, Spain; Cancer & Thrombosis Section, Spanish 
      Society of Medical Oncology (SEOM), Spain.
FAU - Munoz Martin, Andres J
AU  - Munoz Martin AJ
AD  - Medical Oncology Department, Hospital General Universitario Gregorio Maranon, 
      Universidad Complutense, Madrid, Spain; Cancer & Thrombosis Section, Spanish 
      Society of Medical Oncology (SEOM), Spain. Electronic address: 
      andresmunmar@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220620
PL  - Netherlands
TA  - Best Pract Res Clin Haematol
JT  - Best practice & research. Clinical haematology
JID - 101120659
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants
MH  - Heparin
MH  - Heparin, Low-Molecular-Weight
MH  - Humans
MH  - *Neoplasms
MH  - *Venous Thromboembolism
OTO - NOTNLM
OT  - Cancer-associated thrombosis
OT  - Direct-oral anticoagulants
OT  - Low-molecular weight heparins
OT  - Venous thromboembolism
EDAT- 2022/08/28 06:00
MHDA- 2022/08/31 06:00
CRDT- 2022/08/27 21:05
PHST- 2022/06/16 00:00 [received]
PHST- 2022/06/16 00:00 [accepted]
PHST- 2022/08/27 21:05 [entrez]
PHST- 2022/08/28 06:00 [pubmed]
PHST- 2022/08/31 06:00 [medline]
AID - S1521-6926(22)00009-3 [pii]
AID - 10.1016/j.beha.2022.101354 [doi]
PST - ppublish
SO  - Best Pract Res Clin Haematol. 2022 Mar;35(1):101354. doi: 
      10.1016/j.beha.2022.101354. Epub 2022 Jun 20.